Memo Therapeutics develops therapeutic antibodies against virus infections and cancer. The funds from the financing round will be used to complete a Phase II trial of Memo’s lead programme AntiBKV and to prepare manufacturing of the drug for Phase III. Pureos Bioventures led the investment.
MORE
